CA2236809C - Diagnosis of coronary artery spasm-associated diseases - Google Patents

Abstract

The present invention relates to a process for screening for a gene involving a coronary artery spasm-associated disease, which comprises detecting the presence of the relevant nucleotide substituents in the endothelial nitric oxide synthase (eNOS) gene.

The present invention provides the ready diagnosis of a coronary artery spasm-associated disease such as angina, which cannot be conveniently screened by the conventional methods.

Description

DESCRIPTION
Diagnosis of coronary artery spasm-associated diseases Technical Field The invention relates to a technique for a diagnosis of a specific disease, and in particular, to a process for screening for a gene involving a coronary artery spasm-associated disease.

Background Art Intrinsic nitric oxide (intrinsic NO) is a substance which recently has been identified in vivo, and has been shown to act as a vasodilator (18-25), a neurotransmitter (11, 12) or an immunoreactant (13-17). The intrinsic NO
is synthesized from L-arginine due to a family consisting of at least three nitric oxide synthases (NOSs), i.e., neural NOS, endothelial NOS, and macrophage NOS. Neural NOS and endothelial NOS are constitutive, and enhanced in their activity depending on concentrations of intracellular calcium. On the other hand, macrophage NOS is independent of calcium, and activated by inflammation. Early, some researchers determined the gene structure of endothelial cell nitric oxide synthase (eNOS), and reported that the eNOS gene locates at 7q35-36 in chromosome, and is composed of 26 exons, and spans 21 kb (18-25).

Disclosure of Invention Coronary artery spasm is understood to be a pathogenic factor of various ischemic heart diseases such as coronary spastic angina and variant angina (1-6). However, a mechanism of the coronary spasm is not known well.

Thus, the present inventors have carried out investigations for clarifying the mechanism of the coronary spasm, considering that such investigations may be contributed to development of an early diagnosis and treatment of the ischemic diseases to be associated with the coronary spasm.
It should be noted that most of the previous studies have pointed out that a hyper-contractility of smooth muscle is more important in the pathogenic mechanism of the coronary spasm rather than a damage of hemangioendothelium (35).

Acetylcholine generally acts on smooth muscle to contract it, but acetylcholine eventually may lead vasodilatation by means of secretion of nitric oxide (NO) acting on smooth muscle, when the endothelium is uninjured. However, coronary dosage of acetylcholine into patients having coronary spastic angina induces the coronary spasm rather than vasodilatation (7,8). In the connection of the fact, the present inventors previously have demonstrated that the basal secretion of NO caused by acetylcholine is low in the patients having coronary spastic angina (10).

Since nitroglycerin and a nitrous acid medicine can effect vasodilatation in the course of forming NO in vivo, the basal secretion of NO
might be decreased in the coronary artery of the patients having coronary spastic angina, which is supported by the fact that the reaction of vessel in which the NO synthesis is suppressed, to the nitrous acid medicine is supersensitive (9), and the coronary artery in the patients having coronary spastic angina is supersensitive to nitroglycerin. These results would recall the possibility of strong relationship between the coronary spasm and NO, specifically the endothelium where NO is secreted. To date, no one has paid attention to the relationship between the coronary spasm and the endothelium where NO is secreted, only under the circumstance that the decrease in basal secretion of NO is known.

From a different point of view, the present inventors have noticed that the coronary spasm may be caused by a genetic background in the light of the fact that the coronary spasm is more frequent in Japan than in United State of America and Europe (26, 27).

On the basis of the above findings, the present inventors have focused on a gene of one of NOS enzymes which produce intrinsic NO, i.e., endothelial cell nitric oxide synthase (eNOS), examined if the gene is responsible for a development of the coronary spasm, and finally completed the present invention.

Summary of the invention The present invention relates to a process for screening for a gene involving a coronary artery spasm-associated disease, which comprises detecting the presence of one or more nucleotide changes in the gene of endothelial nitric oxide synthase (eNOS), which changes are selected from a group consisting of the changes from guanine (G) to thymine (T) at position 894 and from cytosine (C) to thymine (T) at position 774 of the cDNA
sequence of the eNOS gene, and the changes from thymine (T) to cytosine (C) at position -786, from adenine (A) to guanine (G) at position -922 and from thymine (T) to adenine (A) at position -1468 of the 5'-flanking region of the eNOS gene, as well as the changes at the corresponding positions in the complementary strand thereof. Preferably, the present invention relates to the above process which comprises detecting the presence of two or more nucleotide changes selected from any one of nucleotide changes in the eNOS
gene, and any one of nucleotide changes in the 5'-flanking region thereof, and more preferably, to the above process in which the coronary artery spasm-associated disease is angina, and further preferably, to the above process in which the coronary artery spasm-associated disease is coronary spastic angina.

In one aspect, the present invention relates to the process for screening for the above changes which comprises RFLP method wherein the presence or absence of a cleavage caused by a restriction enzyme is detected.
Particularly, the present invention relates to the process in which the detection of the presence of the changes is performed by amplifying the relevant region to exon 7 in the cDNA coding eNOS by means of PCR, digesting the amplified fragments with the restriction enzyme(s) BanII and/or MboI, and electrophoresing the fragments digested with the enzyme, as well as the process in which the detection of the presence of the changes in exon 6 is performed by treating with the restriction enzyme FokI, the process in which the detection of the presence of the changes at position -786 in the 5'-flanking region of the eNOS gene by treating with the restriction enzyme Msp1, and the process in which the detection of the presence of the changes at position -1468 in the 5'-flanking region of the eNOS gene by treating with the restriction enzyme Mbol.

In one aspect, the present invention relates to a kit for performing the process of the present invention, and specifically, to a kit for diagnosing a coronary artery spasm-associated disease, which comprises an amplification oligonucleotide for amplifying the relevant portion to exon 7 in the cDNA
coding eNOS by PCR, and the restriction enzyme(s) BanII and/or MboI; a kit for diagnosing a coronary artery spasm-associated disease, which comprises an amplification oligonucleotide for amplifying the relevant portion to exon 6 in the cDNA coding eNOS by PCR, and the restriction enzyme FokI; a kit for diagnosing a coronary artery spasm-associated disease, which comprises an amplification oligonucleotide for amplifying a portion encompassing the -786 position in the 5'-flanking region of the eNOS gene by PCR, and the restriction enzyme Mspl; and a kit for diagnosing a coronary artery spasm-associated disease, which comprises an amplification oligonucleotide for amplifying a portion encompassing the -1468 position in the 5'-flanking region of the eNOS gene by PCR, and the restriction enzyme Mbor. It should be noted that the amplification oligonucleotide contained in the kit of the present invention includes oligonucleotides other than those listed in hereinafter Table 1, and can be selected among any oligonucleotides by reference to the genome sequence of eNOS.

In one aspect, the present invention relates to a method for diagnosing a coronary artery spasm-associated disease, which comprises detecting the presence of any one or more nucleotide changes in the eNOS gene as defined above which are responsible for the coronary artery spasmassociated disease.

5 Brief Description of Drawings Fig. I is a photograph which shows the result of the electrophoresis obtained by PCR-SSCP analysis of DNA fragments containing exon 7 in the eNOS gene. Array indicates the shift of the bands.
Fig. 2 is a graph which shows the result of the direct sequencing of the DNA fragments containing exon 7 in the eNOS gene originated from both cases with (mutant type) and without the mutation (wild type). The mutant type represents the heterozygote.
Fig. 3 is a result of the screening of the DNA fragments containing exon 7 in the eNOS gene by PCR-RFLP. The restriction enzyme is BanII and/or Mbol. Fig. 3A is a restriction map thereof. Fig. 3B is a photograph which shows the result of the actual electrophoresis.
Fig. 4 is a photograph which shows the result of the electrophoresis obtained by PCR-RFLP for screening the DNA fragments containing exon 6 in the eNOS gene.
The restriction enzyme is FokI.
Fig. 5 is a photograph which shows the results of the electrophoresis obtained by PCR-RFLP for screening the DNA fragments containing the -786 and -1468 positions in the 5'-flanking region of the eNOS gene. The restriction enzyme is Mspl in the case of the -786 mutation, while it is Mbol in the case of -1468 mutation.

Detailed Description of the invention As stated above, the present inventors have focused on the eNOS gene, examined if the gene is responsible for the development of the coronary spasm, and discovered the following findings:
A) Mutations in exons of the eNOS gene McCarthy Tetrault LLP TDO-RED #8238582 v. 1 1) Mutation in exon 7: guanine G at position 894 of the cDNA encoding eNOS is mutated to thymine M

By means of PCR-SSCP (polymerase chain reaction - single-strand conformation polymorphism) method and direct sequencing method, a point mutation was identified in exon 7 of the eNOS gene obtained from the patient having coronary spastic angina. The mutation represents change from GAG
to GAT, and it corresponds to mutation of the amino acid residue from glutamic acid to aspartic acid (Glu298Asp). By screening of 96 patients having coronary spastic angina and 86 controls for this mutation, it was found that 22 patients and 7 controls carry this mutation, respectively.

2) Mutation in exon 6: cytosine (C) at position 774 of the cDNA encoding eNOS is mutated to thvmine (Tl PCR-SSCP method revealed that this base substitution was found in four patients having coronary spastic angina among ten patients. On the other hand, this base substitution was not found in 9 controls (P=0.03). This base substitution is not accompanied with amino acid change.

B) Mutations in the 5'-flanking region of the eNOS gene Several mutations were found in the 5'-flanking region of the eNOS
gene, and the relationship between these mutation and coronary spastic diseases was evaluated to obtain the following results.

1) Thymine (T) in the 5'-flankingregion (-786) is mutated to cytosine (C) PCR-SSCP method revealed that this base substitution was found in 34 patients having coronary spastic angina among 123 patients (27.6%), while this base substitution was found in only 4 controls among 86 controls (4.7%) (P<0.0001).

2) Adenine (A) in the 5'-flanking region (-922) is mutated to guanine Gl PCR-SSCP method revealed that this base substitution was found in 31 patients having coronary spastic angina among 104 patients (29.1%), while this base substitution was found in only 3 controls among 83 controls (3.6%) (P<0.0001).

3) Thymine (T) in the 5'-flankin region (-1468) is mutated to adenine(A) PCR-SSCP method revealed that this base substitution was found in 26 patients having coronary spastic angina among 98 patients (26.5%), while this base substitution was not found in 26 controls (0%) (P<0.0006).

The above mutations associated with the eNOS gene are useful in diagnosis of coronary spasm-associated diseases.

The term "coronary spasm-associated disease(s)" in the present specification includes angina, in particular coronary spastic angina, variant angina, unstable angina, effort angina, rest angina, acute myocardial infarction, microvasulor disease, and the like.

The relationship between the coronary spasm and the mutations associated with the eNOS gene has been demonstrated by the present invention, and therefore, when the mutations in the eNOS gene or in the 5'-flanking region thereof which is obtained from a patient suspected to have coronary spasm-associated diseases is detected, it can estimate that the patient in question may have the risk factor of the coronary spasm-associated diseases.
Only one of these mutations is sufficient for an indicator for the diseases, and two or more mutations may be better indicator. Further, it has been found that detection of the mutations both in the eNOS gene region and the 5'-flanking region thereof lead estimation that coronary spasm-associated diseases be severe.

As shown above, the present invention provides a process for screening for a gene involving a coronary artery spasm-associated disease, which comprises detecting the presence of one or more nucleotide changes in the gene of endothelial nitric oxide synthase (eNOS), which changes are selected from a group consisting of the changes from guanine (G) to thymine (T) at position 894 and from cytosine (C) to thymine (T) at position 774 of the cDNA sequence of the eNOS gene, and the changes from thymine (T) to cytosine (C) at position -786, from adenine (A) to guanine (G) at position -922 and from thymine (T) to adenine (A) at position -1468 of the 5'-flanking region of the eNOS gene, as well as the changes at the corresponding positions in the complementary strand thereof.

The term "the changes at the corresponding positions in the complementary strand thereof" means, for example in the case of the nucleotide change from guanine (G) to thymine (T) at position 894 in cDNA

of the eNOS gene, then the change wherein cytosine (C) at the position in the complementary strand corresponding to the 894 positiori is mutated to adenine (A).

First, the method for obtaining the eNOS gene and the 5'-flanking 10. sequence from a patient is outlined as below.

All biopsy can be used as a sample for obtaining the gene, and typically a white blood cell sample, and additionally biopsy of liver also can be used. The sample is treated with proteinase K-SDS to effect proteolysis and denaturation, and then extracted with phenol/chloroform to give genomic DNAs(+RNAs). If desired, the RNAs can be removed by RNase.

Then, PCR is performed using any one of the primers as shown below to amplify the genomic DNA. Then, the presence of the mutations is confirmed by the following procedure for detection of nucleic acid mutation.
1) RFLP method (restriction fragment length polymorphism) 2) PCR-SSCP method (single-stranded DNA conformation polymorphism analysis) 3) ASO hybridization method (allele specific oligonucleotide hybridization) The PCR products are blotted on a support such as a nylon filter, and hybridized with a synthetic oligonucleotide probe of about 18-mers having a base sequence containing the mutation to be detected, which may be labeled with a radioisotope or biotin to give a signal. Then, when the filter is washed according to a Tm value of the probe, it is possible to detect a mismatch of one base pair, since the mismatch would make the hybrid melted.
This method is typical as a method for detecting a specific mutation of base by PCR.

4) Sequencing method 5) Southern blot method This is the typical method for detecting mutations which comprises digesting a DNA with a restriction enzyme, developing over electrophoresis, and hybridizing with a probe. This method includes both genomic Southern blot and PCR Southern blot methods. The latter, which uses the same principle as the method (3) is advantageous in accuracy in that it can provide information of migration.

6) ARMS (amplification refracting mutation system) In PCR, a primer anneals -to a template DNA, and then, a DNA
polymerase produces a complementary DNA from 5' to 3' end. ARMS is based on the principle that amplification efficacy of PCR is decreased and the PCR products cannot be detected on gel electrophoresis when the 3'-end of the primer makes mismatch to the template DNA. When the primer having a mutation to be detected at its 3'-end is used in amplification of PCR, it is possible to detect the mutation by examining the presence or the absence of the amplified products.

7) DGGE (denaturing gradient gel electrophoresis) This method is based on the principle that a heteroduplex containing a mismatch in PCR products may dissociates more readily than a homoduplex.
In this method, a double-stranded DNA containing a mismatch, i.e., a mutation, is detected as migration on the electrophoresis gel for the reason that migration of such DNA is poor on the gel in the course of dissociation, which is further accelerated by elevating the density gradient of an urea and formamide in the developing polyacrylamide gel.

8) RNase A cleavage method RNase A (ribonuclease) is an enzyme which does not decompose a double-stranded RNA or an RNA/DNA hybrid, and selectively decomposes a single-stranded RNA. So, when an RNA probe labeled with 32P is hybridized with a sample DNA which have been denaturated -into a single-10.

stranded, the hybrid is treated with RNase A, and the products are developed over electrophoresis, then two bands may be detected for reason that singlestranded RNA
derived from the RNA probe hybridized with the mutant DNA is cleaved by RNase A.
9) Chemical cleavage method "C" nucleotide and "T" nucleotide in the mismatch site of a hybrid DNA are modified by hydroxylamine and osmium tetra-oxide, respectively, and then the modified DNA is treated with piperidine to cleavage the sugar residue. A hybrid of a labeled probe and the sample DNA is applied to this procedure, and developed over electrophoresis.
When the mutation is present in the sample DNA, the labeled probe is detected in smaller size. In the case of detection of Glu298Asp, the mismatch site is C-T, and therefore the reverse sequence of the wild type also can be used for detecting the mismatch.
10) ligase method This method is based on the principle that two kinds of oligonucleotides can not ligated to each other with DNA ligase when the template DNA has mismatch(es) at the binding site.
i) LMGD (ligase-mediated gene detection) For example, one oligo DNA is labeled with 32P, while the other DNA is labeled with biotin. Both are ligated each other and the ligated product is collected by absorption to streptavidin. When they safely ligate each other, in other words, any mismatch is not formed, then they can be detected since radioactivity of 32P becomes higher.
ii) LCR (ligase chain reaction) By repeating the above ligation except of using thermo-stable ligase, an oligo DNA is annealed with a DNA strand, similarly to in PCR, and therefore higher sensitive detection of the mutation is facilitated.

Best Mode for Carrdng Out the Invention McCarthy Tetrault LLP TDO-RED #8238582 v. I

ll 1. Mutation in exon 7 The mutation in exon 7, specifically the mutation from guanine (G) to thymine (T) at position 894 of the cDNA encoding eNOS represents change from GAG to GAT, both which form the different restriction sites. So, the presence of the mutation can be determined using a restriction enzyme.
Specifically, digestion of the amplified products with either the restriction enzyme BanII or Mbol enables to detect the presence of the mutation. More specifically, the mutation is found to be present when the restriction enzyme BanIl can cleavage the site in question, while the mutation is found to be absent when the restriction enzyme Mbol can cleavage the site in question.
Alternatively, since the mutation from guanine (G) to thymine (T) at position 894 of the cDNA encoding eNOS corresponds to the mutation in the amino acid from glutamic acid to aspartic acid (G1u298Asp), the change of the amino acid sequence of eNOS, i.e., the change from glutamic acid to aspartic acid at position 298 of the amino acid sequence of eNOS may be an indicator.

2. Mutation in exon 6 The mutation in exon 6, specifically the mutation from cytosine (C) to thymine (T) at position 774 of the cDNA encoding eNOS gives different restriction site each other, so the presence of the mutation can be determined using a restriction enzyme. Specifically, digestion of the amplified products with the restriction enzyme Fokl enables to detect the presence of the mutation. More specifically, the mutation is found to be present when the products can be digested with the restriction enzyme FokI, while the mutation is found to be absent when the products cannot be digested with Fokl.

3. Mutation at position -786 in the 5'-flanking region The mutation in the 5'-flanking region of the eNOS gene, specifically the mutation from thymine (T) to cytosine (C) at position -786 also gives different restriction site each other, so the presence of the mutation can be determined using a restriction enzyme. Specifically, digestion of the amplified products with the restriction enzyme MspI enables to detect the presence of the mutation. More specifically, the mutation is found to be absent when the restriction enzyme Mspl cleaves the amplified products on one site, while the mutation is found to be present when Mspl cleaves the amplified products on two sites.
4. Mutation at position -1468 in the 5'-flanking region The mutation in the 5'-flankin region of the eNOS gene, specifically the mutation from thymine (T) to adenine (A) at position -1468 also gives different restriction site each other, so the presence of the mutation can be determined using a restriction enzyme.
Specifically, digestion of the amplified products with the restriction enzyme Mbol enables to detect the presence of the mutation. More specifically, the mutation is found to be absent when the restriction enzyme Mbol cleaves the amplified products on one site, while the mutation is found to be present when MboI cleaves the amplified products on two sites.

Examples Example 1 Detection of the mutation in exon 7 in the eNOS gene Subjects are 96 patients having coronary spastic angina and 86 controls. All of the patients having coronary spastic angina undergo spontaneous stroke at rest (male 53, female 43, mean age 61, ages 33-86). Heart catheter examination has been performed on all patients to confirm coronary spasm induced by acetylcholine or ergonovine over coronary arteriography, as well as to confirm significant ST-T change over electrocardiogram (7,8). Significant constriction in coronary artery were not found in all patients (>75%).
Among 86 controls, 61 construct a breast pung group, 12 construct a group which is abnormal in electrocardiogram, and 13 construct a group 30 having mild valvular disease (male 35, female 51, mean age 61, age 13-83).

McCarthy Tetrault LLP TDO-RED #8238582 v. I

Coronary arteriography revealed that no one in the controls has significant constrictions. When coronary spasm-inducing test was performed on 61 subjects of the breast pung group and 12 subjects of the group which is abnormal in electrocardiogram by coronary dosage of acetylcholine or ergonovine, all subjects are negative. The control does not include subjects having myocardial infarction, syndrome X, myocardiopathy, and cardiac insufficiency.

(1) Examination of the eNOS gene mutation by PCR-SSCP
i) Isolation of DNA

Peripheral venous blood was collected from 10 patients having typical coronary spasm and 9 controls, and the DNAs were extracted from the white blood cells (28), using DNA extraction kit DNAQUICH [DAINIPPON
SEIYAKU].

ii) PCR step Referring to the structure of the eNOS gene which has been reported (18-25), PCR-SSCP method was performed on all exons in the eNOS gene (29).

All primers were prepared on the basis of the sequence of introns to flank each exon. All primers used in this step are shown in Table 1.

Table 1. Primers for all 26 exons of endothelial cell nitric oxide synthase (eNOS) gene used for polymerase chain reaction - single-strand conformation polymorphism (PCR-SSCP) 1. 5'-CAGCAGAGTGGACGCACAGTAAC 15. 5'-GTGACAACCTTGTCTTTGTCC
5'-TTGTTGCCCACCTGC7CCTAGCTG 5'-TCGTCAGTGGAGCTCCCTTT
(217) (231) 2. 5'-AACCCTTCCTGATGACCCTATCCC 16. 5'-AAAGGGAGCTCCACTGACGA
5'-CTTACCCACCCTITCCCTGGAGAC 5'-AGAATCAGGGCAGAGTGAGG
(200) (284) 3.5'-TCCTGACCTTTGCACTCCCTCGA 17.5'-AGCAAGACGCAGTGAAGCCG
5'-ATGGGAAGGTCGTCACGGGG7TTC 5'-TGGCCCCAGAGTGCTTTAGT
(250) (275) 4. 5'-ACAACTTCCTGCTTGTCCCCTTCC 18. 5'-ACTAAAGCACTCTGGGGCCA
5'-ACCCCGCTCCCCTTTI GGTA 5'-AGGGTCAGGGTG7TCAGGACA
(259) (203) 5. 5'-TCTGGAGCTGATACTCAAGACCCC 19. 5'-TGTCCTGAACACCCTGACCCT
5'-CGCATGGGGAAAGAGCTGGTCAGA 5'-GCTGGTGTGCCCTGTTGCTT
(246) (322) 6. 5'-TCTGACCAGCTCTTTCCCCATGCG 20. 5'-CTCCCTGTGCACTATCCCCA
5'-CCACTGGTTTCCTCATTCTCCACC 5'-TCTAGCCCCTGTGCCTCATT
(232) (329) 7. 5'-AAGGCAGGAGACAGTGGATGGA 21. 5'-TCCAACCCACTGCATCCTGC
5'-CCCAGTCAATCCC'TTTGGTGCTCA 5'-TGCTCCTGCTTGTTGCCTCA
(248) (259) 8. 5'-GCTGATCCCACACCCCAACA 22. 5'-TGAG-GCAACAAGCAGGAGCA
5'-TGCCTfGGACAGGTGCATTC 5'-CACCAAGTCITCCATCTCAC
(250) (202) 9. 5'-TGATCACCTCTGTCCCTACCGA 23. 5'-ATGGAGTGTCTCTCCTGCCA
5'-ATGCAAACCCTTTGCCTTCCTG 5'-TTCAGGCAGTCCTTTAGTGC
(189) (173) 10. 5'-AAGAATGGGCGAGGTCTGTGGGT 24. 5'-AGAAGAGCCTTCCCAACCCG
5'-CAGGGGCTGCTTAGAATTAGAGC 5'-ATCTTCAGGTTACCATTGCG
(311) (219) 11. 5'-TCCCTCCCAACCCATCATCTCTCT 25. 5'-CAGACCTACGTGCAGGACAT
5'-AGTGGTAGGCCCAGAACACTGCT 5'-ACCTTAGCAGGAACCCCGCA
(208) (276) 12. 5'-CAGGACACCCTCACACCTTCCTCT 26-1. 5'-G77CTGATCCACTGTGCTCT
5'-TCTTTCTAGCTCCCTGCTCCC 5'-TCTCCCGGAAC'1'GGAAGGGA
(210) (226) 13. 5'-ACAGCACCCAGGACATCTGTCITC 26-2. 5'-ACACCAACAGCCCCTGAGAG
5' AGCCCCTITCCTGGAAGTTCTCA 5'-TGGCAGTAGGCCCTGGGGTA
(163) (273) 14. 5' TGATGTCAAACACTCCCCTCG 26-3. 5'-TTAATCTGGAAGGCCCCTCC
5'-AAAACGGACTTGAGGCACAG 5' GAGGGAGACTCCGITTCAAA
(267) (178) Top: sense primer,bottom: antisense primer in each primer set. Base-pair length of amplified fragments in parentheses. Three primer sets were used in the analysis of exon 26.

To a solution in a total volume of 5 l containing 50 mmol/L KCL, mmol/L Tris-HCL (pH 8.4), 0.75 mmol/L MgC12, 0.1 mmol/L dNTPs, 0.2 ml a-[32P]dCTP(0.2m1), 5 pmol each primer, and 0.01U Taq polymerase (GIBCO BRL, Life Technologies Inc., MD USA) in each tube was added 30 5 ng of DNA from the patients.

PCR procedure was performed as follows: one cycle of 2 minutes at 94 C; 30 cycles of 30 seconds at 94 C, 30 seconds at 55-58 C, and one minute at 72 C ; and the resulting amplified products were stored at 4 C C.
Amplification of exon 7 was conducted at 57 C C.
10 iii) SSCP step Electrophoresis was performed under three conditions in which one is 5% glycerol gel at room temperature, and the others are 5% and 10%
glycerol gel at 4 C C.

The glycerol gels were prepared as follows:

15 1) preparing a 5% solution containing 49:1 of acrylamide and N,N'-methylene-bis-acrylamide.

2) preparing 0.5 x TBE (10 x TBE is diluted 20 times: 108 g of Tris(hydroxymethyl)aminomethane + 55 g of boric acid + 40 ml of 0.5 M
EDTA + a water of which volume makes a total volume 500 ml).

20 3) preparing a gel by adding 160 l of 10% APS (ammonium peroxodisulfide) and 60 l of TEMED (N,N,N',N'-tetramethylethylenediamine) to a solution of 5% or 10% glycerol.

iv) Result The result obtained by the amplification of exon 7 is shown in Fig.
1. This demonstrates a band-shift of the fragment comprising exon 7 in three of 10 coronary spastic angina patients. On the other hand, no shift was shown in controls.

(2) Analysis of the mutant gene by direct sequencing method DNAs of the patients found to have the mutation and the controls found to have no mutation by PCR-SSCP in the step (1) were again amplified according to the same condition as that of the step (1), and the amplified products were purified by Wizard PCR Preps DNA purification system (Wizard PCR Preps DNA Purification System, Promega, USA). Then, the base sequence was determined by an autosequencer produced by ABI [USA].

By analysis of the mutant DNA and the wild DNA by direct sequencing method, point mutation from guanine (G) to thymine (T) at position 894 in exon 7 of the eNOS cDNA was found. This mutation was confirmed in three patients which had been found to have the mutation. The point mutation represents missense mutation which corresponds to the change from glutamic acid to aspartic acid (G1u298Asp). The result of the direct sequencing is shown in Fig. 2. This figure includes the results of the wild type without the mutation and the heterozygote type.

(3) Screeningfor the mutation from "G" to "T" by PCR-RFLP

After the missense mutation inducing Glu298Asp was found in exon 7 of the eNOS gene as shown in the step (2), all of 96 patients having coronary spastic angina and 86 controls were screened for the mutation.
This screening was performed by PCR-RFLP (polymerase chain reaction -restriction fragment length polymorphism). Two types of the restriction enzyme, BanII and MboI (purchased from TAKARA) were used in order to prevent any mistakes based on the incomplete cleavage by restriction enzymes.
Exon 7 of the eNOS gene from all cases was amplified according to the procedures of (ii) in the step (1). The amplified fragments containing exon 7 spanned 248 bp. Then, the amplified fragments were digested with either BanII or MboI according to instructions of the manufacture. The digested products were elctrophoresed on 4% Nusieve GTG agarose gel to give a band.

The results could be classified into three patterns as shown in Fig. 3.
Fig. 3A is a restriction map, and Fig. 3B is a photograph of the result of the actual electrophoresis. As shown in Fig. 3B, BanII gives two fragments having 163 bp and 85 bp in length and MboI gives one band having 248 bp which is not cleavaged, in the wild type without the mutation. This demonstrates that the wild type with the mutation has one restriction site of BanII and no restriction site of Mbol.

In the case of homozygote having T/T at position 894 of the eNOS
cDNA, BanII gives no cleavage (248 bp), while Mbol gives two fragments of 158 bp and 90 bp in length. This demonstrates that the homozygote has no restriction site of BanII, and one restriction site of Mbol.

There are some cases which have given three bands of 248 bp, 163 bp and 85 bp in length by BanII, and 248 bp, 158 bp and 90 bp in length by Mbol. This is regarded as to the heterozygote (G/T) since each BanII and Mbol merely gives one cleavage site in either band.

On the basis of the three patterns as shown above, frequency of the eNOS gene Glu298Asp mutation was examined on all cases of the coronary spastic angina and control groups. Digestion with both enzymes was performed on all cases. The results obtained by using these two enzymes are consistent among all cases.

Glu298Asp mutation was found in 22 of 96 coronary spastic angina patients (23%), in which one is the homozygote and 21 are the heterozygote.
On the other hand, the mutation was found in 7 of 86 controls (8%), all of which are the heterozygote.

(4) Statistic analysis: relationship between coronary spasm and Glu298Asp mutation or other risk factors The mutation frequency obtained in the step (3) was compared with frequency of other coronary risk factors including age, sex, high blood pressure, diabetus melitus, haypercholesterolemia, body mass index and smoking between the control and coronary spastic angina groups by Chi-square analysis and unpaired t-test with Fisher's exact probability. Further, multivariate analysis (multiple logistic regression analysis) was performed to examine whether factor is mostly associated with the coronary spasm by SPSS

Advanced Statistics 6.1 for the Macintosh (SPSS Japan Inc., Japan). Dummy variables were used as all independent variables which is as followed. Each numerical value represents means SD.

Sex; 0: male, 1: female Age; 0: under 60, 1: 60 or above Body mass index; 0: under 26, 1: 26 or above Cholesterolemia; 0: normal, 1: Haypercholesterolemia (threshold, 260 mg/dl) Smoking; 0: nonsmoker, 1: smoker Hypertension; 0: normal, 1: high (threshold, 160/95 mmHg) 10. Diabetus melitus; 0: absent, 1: present (threshold, 140 mg/dl of fasting blood glucose or 200 mg/dl in OGTT) The results of Chi-square analysis and the results of analysis using forward stepwise selection (Wald) are shown in Tables 2 and 3, respectively, wherein p=0.05 is regarded as a significant value in statistics.

Results of the statistic analysis Of the relationships between coronary spasm, and G1u298Asp mutation or other risk factors such as age, sex, high blood pressure, diabetus melitus, haypercholesterolemia, body mass index and smoking, sex (p=.035), smoking (p=.00001) and Glu298Asp mutation (p=.005) were significant as shown in Table 2.

Table 2. Clinical characteristics of the study patients; comparison between the control and coronary spastic angina groups Control Spasm p value n=86 n=96 Age 61 12 61 11 .97*
Men : Women 35:51 53:43 .035**
Body mass index 23.4 3.7 23.1 3.0 .48*
High blood pressure 29/85 35/94 .39**
Diabetus melitus 15/84 10/93 .13**
Hypercholesterolemia 31/82 31/93 .32**
Smokers 17/84 50/95 .00001**
Glu298Asp mutation 7/86 22/96 .005**
*Unpaired t-test and **Chi-square analysis with Fisher's exact probability were performed.

The results of multivariate analysis (multiple logistic regression analysis) is shown in Table 3. Table 3 shows that smoking is the first factor, which shows the responsibility for coronary spasm (p=.0005), and G1u298Asp mutation is the second factor (p=.0272). Multiple logistic regression 5 analysis does not show any significant relationship between sex and coronary spasm.

Table 3. Parameters associated with coronary spastic angina by multiple logistic aegression analysis; final variables in the equation using forward stepwise regression analysis (Wald) Variable 18 SE Wald df Significance R Exp(,8) N
N
~
Smoking 1.2342 .3529 12.2316 1 .0005 .2120 3.4355 GIu298Asp 1.0746 .4866 4.8771 1 .0272 .1124 2.9288 Constant -.4371 .2139 4.1747 1 .0410 Example 2 Detection of the mutation in exon 6 of the eNOS gene According to the procedures of Example 1, genomic DNA was isolated from 10 coronary spastic angina patients and 9 controls. PCR was performed using the primers described in Table 1, and then SSCP procedure was performed to detect the mutation in exon 6. Then, the exon 6 was sequenced directly to identify the substitution of the base from cytosine (C) to thymine (T) at position 774 in the cDNA of the eNOS gene.

This substitution of the base was found in 4 of 10 patients having coronary spastic angina, while this substitution was not found in 9 controls (p=0.03). This substitution is not associated with any change of amino acid.
Example 3 Detection of the mutation in the 5'-flanking region of the eNOS gene 1~
The procedures of Example 1 were substantially repeated except using the following primers, to identify the substitution of the base from thymine (T) to cytosine (C) in the 5'-flanking region (-786).
PCR-SSCP(-585--820bp ; 236bp) 5' side primer: 5'-ATGCTCCCACCAGGGCATCA-3' 3' side primer: 5'-GTCCTTGAGTCTGACATTAGGG-3' This substitution of the base was found in 34 of 123 patients having coronary spastic angina (27.6%), while this substitution was found in only 4 of 86 controls (4.7%). (P<0.0001) Example 4 Detection of the mutation in the 5'-flanking region of the eNOS gene (2) The procedures of Example 1 were substantially repeated except using the following primers, to identify the substitution of the base from adenine (A) to guanine (G) in the 5'-flanking region (-922).

PCR-SSCP(-801--1008bp ; 208bp) 5' side primer: 5'-TCAGTCTCTGAGGTCTCGAA-3' 3' side primer: 5'-TGATGCCCTGGTGGGAGCAT-3' This substitution of the base was found in 31 of 104 patients having coronary spastic angina (29.1%), while this substitution was found in only 3 of 83 controls (3.6%). (P<0.0001) Example 5 Detection of the mutation in the 5'-flanking region of the eNOS gene (31 The procedures of Example 1 were substantially repeated except using the following primers, to identify the substitution of the base from thymine (T) to adenine (A) in the 5'-flanking region (-1468).

PCR-SSCP(-1214~--1490bp ; 221bp) 10. 5' side primer: 5'-CCATTAACTGGAACCTAGGAA-3' 3' side primer: 5'-AGCCTGGGCTTTGTCCCATGA-3' This substitution of the base was found in 26 of 98 patients having coronary spastic angina (26.5%), while this substitution was not found in 26 controls (0%). (P<0.0006) Example 6 Screening for the mutations The five mutations identified in the above working examples can be screened in a large way by ASO hybridization (Hybridization with Allelic-Specific Oligonucleotides) method, for example. This ASO hybridization method for extensive screening is illustrated below:

1) performing PCR similarly to SSCP. In this case, the final volume is 20 .l.
Composition of the reaction and cycle condition are the same as those in Example 1;

2) taking a 10 l aliquot of the PCR reaction, immobilizing a 100 l aliquot of 200 l of 0.5 M NaOH (1.5 M NaCI + 25 mM EDTA2Na) on a nylon membrane for the wild type, and then immobilizing the residual 100 l on a nylon membrane for the mutant type;

3) packing each of the immobilized nylon membranes into the different hybribag, adding the pre-hybridization solution (3 x SSPE, 5 x Denhart's regent, 0.5% SDS, 1 g/ l herring sperm DNA) to the bags, and incubating the bags at 65 C for two hours;

4) introducing the normal probe labeled with 32P (5 x 106 dpm/ml) and the abnormal probe without any labels in five times volume into one bag, while introducing the abnormal probe labeled with 32P (5 x 106 dpm/ml) and the normal probe without any labels in five times volume into the other bag;

5) incubating each of bags at 60 C for 30 minutes, and further incubating the same for additional one hour as decreasing the temperature from 60 C to X C wherein X is 53 in Example 3, 50 in Example 4, 46 in Example 5;

6) taking the nylon membranes out of the bags, and incubating the membranes twice in 2 x SSPE (0.1% SDS) at room temperature for 10 minutes, and then incubating them once in 5 x SSPE (0.1%SDS) at X C for 10 minutes.

7) wrapping the nylon membranes with saran wrap, overlaying them onto X-ray film, and developing the X-ray film (autoradiography).

Examale 7 Screening for the mutations in exon 6 and the 5'-flanking region of the eNOS gene By direct sequencing method described in Examples 2, 3 and 5, the substitution of the base from cytosine (C) to thymine (T) at position 774 in the cDNA'of the eNOS gene, as well as the substitutions from thymine (T) to cytosine (C) at position -786 and from thymine (T) to adenine (A) at position -1468 in the 5'-flanking region of the eNOS gene were identified. Screening for these mutations was performed by PCR-RFLP method. Oligonucleotides and conditions for the amplification in this PCR are shown in Tables 4 and 5:

Table 4 Base Sequence of Oligonucleotides for PCR Amplification (a) exon 6 5'-TCTGACCAGCTCTTTCCCCATTCG-3' (sense) 5 5'-CCACTGGTTTCCTCATTCTCCACC-3' (anti-sense) (b) 5'-flanking region (-1468) 5'-CTCCAGCCCCTCAGATGA-3' (anti-sense 1) 5'-TCCAGCCCCTCAGATGG-3' (anti-sense 2) 5'-GTCCTTGAGTCTGACATTAGGG-3' (sense) 10 (c) 5'-flanking region (-786) 5'-AATGAGTCATCCTTGGTCATG-3' (anti-sense) 5'-GGGTTTGTAGTTCTGTGT-3' (sense 1) 5'-GGGTTTGTAGTTCTGTGC-3' (sense 2) 15 Table 5 PCR amplification conditions region for temperature time* cycle amplification ( C ) (seconds) De.l) An.2) Ex.3) De.l) An.z) Ex.3) 20 exon 6 94 63 72 60 60 60 32 5'-flanking region 94 58 72 45 75 60 32 5'-flanking region 94 60 72 45 75 60 32 PCR reaction was performed in a volume of 25 ml of buffer (composition: 10 25 mM Tris-HCl pH9.0, 50 mM KCI, 1.5 mM MgC12, and 0.1% Triton X-100;
0.5 mM each of the PCR primers; 200 mM deoxynucleotide; 0.5 U Taq polymerase).

*: Temperature was controlled on a DNA Thermal Cyclar 480 (Perkin-Elmer Cytus).

De.l): denaturation; An.2) : annealing; Ex.3) : extension (1) Mutation in exon 6 According to the procedures of the step (2) in Example 1, exon 6 of the eNOS gene in a sample was amplified using the primers described in Table 5 and the condition for amplification described in Table 5. The resulting amplified fragment (232bp) was digested with FokI according to instructions of the manufacture, and the digested products were electrophoresed on 10% polyacrylamide gels to identify the bands. Since FokI can cleaves only mutant gene, it was found that the homozygote having C/C gives the band of 232 bp, the heterozygote having C/T gives the bands of 232 bp, 133 bp and 99 bp, and the homozygote having T/T gives the bands of 133 bp and 99 bp. The results of the screening by PCR-RFLP is shown in Fig. 4.

(2) The mutation at Position -786 in the 5'-flanking region According to the procedures of the step (2) in Example 1, a portion encompassing the mutation at position -786 in the 5'-flanking region of the eNOS gene in a sample was amplified using the primers described in Table 5 and the condition for amplification described in Table 5. The resulting amplified fragment (354bp) was digested with MspI according to instructions of the manufacture, and the digested products were electrophoresed on 10%

polyacrylamide gels to identify the bands. MspI cleaves the homozygote of the wild type gene (T) at one site to give two bands of 196 bp and 158 bp.
On the other hand, Mspl cleaves the homozygote of the mutant gene (G) at two sites to give three bands of 158 bp, 154 bp and 44 bp. The results of the screening by PCR-RFLP is shown in Fig. 5.

(3) The mutation at position -1468 in the 5'-flanking reg;ion According to the procedures of the step (2) in Example 1, a portion encompassing the mutation at position -1468 in the 5'-flanking region of the eNOS gene in a sample was amplified using the primers described in Table 5 and the condition for amplification described in Table 5. The resulting amplified fragment (627bp) was digested with MboI according to instructions of the manufacture, and the digested products were electrophoresed on 10%
polyacrylamide gels to identify the bands. Mbol cleavages the homozygote of the wild type gene (T) at one site to give two bands of 515 bp and 112 bp.
On the other hand, MboI cleavages the homozygote of the mutant gene (A) at two sites to give three bands of 515 bp, 61 bp and 41 bp. The results of the screening by PCR-RFLP is shown in Fig. 5.

(4) The mutation at position -922 in the 5'-flanking region This mutation was detected by PCR-SSP (Sequence-Specific Primer). Each of two types of primers for forward and backward extension (totally four species) were designed to extend from "A" or "G" at position -922 to 3' direction. These primers are the same as those described in (b) and (c) in Table 4. A sense and an anti-sense primers (two species) to be paired to these primers were designed so that the region to be amplified contains the mutation at position -1468 and -786, respectively. The PCR procedure revealed that the homozygote containing A/A at position -922 can be amplified by only primer having "A" or "T" (complementary sequence) at the 3' origin, while the homozygote containing G/G can be amplified by only primer having "G" or "C" (complementary sequence) at the 3' -side terminal.

The resulting amplified fragments are the same as those obtained in the above (2) and (3). By examination of the amplified fragments in some samples, it was found that the amplified fragment (354 bp) obtained in the above (2) which is derived from the allele having "A" at position -922 (wild type) gives only wild type having "T" at position -786, while the amplified fragment (354 bp) obtained in the above (2) which is derived from the allele having "G" at position -922 (mutant type) gives only mutant type having "G"
at position -786. Similarly, the amplified fragment (627 bp) of the above (3) which is derived from the allele having "A" at position -922 (wild type) gives only wild type having "T" at position -1468, while the amplified fragment (627 bp) of the above (3) which is derived from the allele having "G" at position -922 (mutant type) gives only mutant type having "A" at position -1468. These findings show that in a certain embodiment that all of the above mutations in the 5'-flanking region may form a linkage to reside on the same allele, indicating that when either one of three mutations are detected, then the other two mutations can be present.

Discussion As shown above, the present inventors have hypothesized that mutations in the eNOS gene should be responsible for a decrease of activities of NOS, which decrease may induce coronary spasm, and carried out some experiments for supporting our hypothesis. When the hypothesis is true, it is 1G consistent with the fact that the coronary spasm does not occur only at one branch, but also at multiple branches (8). Mutation Glu298Asp as shown in Example 1 have been previously reported by Marsden, et.al. (24), but therein the significance of the mutation was not described.

In Example 1, the mutation Glu298Asp was found in 23% of the coronary spastic angina patients, while found in 8% of the controls, indicating that the frequency of the mutation in the angina group is significantly high compared with that in the control group. The result of the multivariate analysis shows that the relationship between the coronary spasm and the mutation Glu298Asp is regarded as significant.

It can be considered that since the rate of this mutation in the coronary spastic group is merely 23%, the coronary spasm of the residual 77%
patients may be caused by pathogenic factors other than this mutation. The present inventors have hypothesized that mutations may exist in regions including the promoter and introns other than exon 7 of eNOS which is described in Example 1, and performed some experiments, so as to find the results to support our hypothesis (Examples 2-5). Accordingly, when the relationship of these mutations is more specifically examined, it is possible to lead more reliable diagnosis for coronary spasm-associated diseases.

Alternatively, it can be considered that the coronary spasm may be caused by not only the eNOS gene, but also other genes. Further, it should be noted that the coronary spasm may be caused by not only genetic factors, but also environmental factors, for the patients having the familial attack type of coronary spasm are relatively less. Smoking is shown to be one of the risk factors of the coronary spasm in Example 1. This result is consistent with the previous reports (30, 31). The results of the multiple logistic regression analysis in the present specification shows that the smoking is the most dominant factors among all risk factors including the mutation, indicating that the environmental factors are extremely important in pathogenesis of the coronary spasm. Other researchers also have indicated that the smoking causes endothelial damages (32, 33).

The mutation Glu298Asp has been found in 8% of the controls (786, Example 1). This reason is not fully understood, and it is noted, however, that since six subjects are non-smokers among seven subjects which have the mutation, these six subjects are unrelated to the smoking which is the strong risk factor. Difficulty in diagnosis of the coronary spasm also should be taken account. Specifically, the coronary spasm may be overlooked for some reasons, and the case which should have been assigned to the coronary spastic group is assigned to the control group for the following reasons:

1) The attack is liable to be overlooked because the attack often occurs midnight to early morning, and generally it dose not occur daytime;

2) Administration of acetylcholine into coronary artery cannot always induce coronary spasm, and the coronary spasm is often dependent on disease activity of coronary spastic angina.

3) Over two third attacks of coronary spasm is silent (subclinical);

4) Even if the result of examination does not show to be coronary spastic angina, the angina may occur in future. On the contrary, the coronary spastic angina group herein is population of the cases which have been definitely diagnosed to have the coronary spasm by coronary arteriography.

By the present invention, it is demonstrated that the coronary spasm is caused by genetic factors as well as environmental factors for the first time, and better diagnostic method for coronary spasm-associated diseases can be provided.

The literatures referred to herein are listed as following:
5 Literatures 1) Hillis LD, Braunwald E, Coronary-artery spasm. N Engl J Med.
1978;299:695-702 2) Conti CR. Coronary artery spasm and myocardial infarction. N Engl J
Med. 1983;309:238-239 10 3) Yasue H, Omote S, Takizawa A, Nagao M. Coronary arterial spasm in ischemic heart disease and its pathogenesis. A review.Circ Res. 1983;52 (Supple I):147-152 4) Maseri A, Davies G, Hackett D, Kaski JC. Coronary artery spasm and vasoconstriction. The case for a distinction. Circulation. 1990;81:1983-1991 15 5) Yasue H, Nagao M, Omote S, Takizawa A, Miwa K, Tanaka S. Coronary artery spasm and Prinzmetal's variant form of angina induced by hyperventilation and tris-buffer infusion. Circulation. 1978;58:56-62 6) Yasue H, Omote S, Takizawa A, Nagao M, Miwa K, Tanaka S.
Circadianvariation of exercise capacity in patients with Prinzmetal's variant 20 angina. Role of exercise-induced coronary artery spasm. Circulation.
1979;59:938-948 7) Yasue H, Horio Y, Nakamura N, Fujii H, Imoto N, Sonoda R, Kugiyama K, Obata K, Morikami Y, Kimura T. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the 25 parasympathetic nervous system in the pathogenesis of coronary artery spasm.
Circulation. 1986;74:955-963 8) Okumura K, Yasue H, Horio Y, Takaoka K, Matsuyama K, Kugiyama K, Fujii H, Morikami Y. Multivessel coronary spasm in patients with variant angina: a study with intracoronary injection of acetylcholine. Circulation.
30 1988;77:535-542 9) Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev.. 1991;43:109-142 10) Yasue H. Pathogenesis and clinical features of coronary spasm. J Jap Soc Intern Med 1995;84:1407-1415 11) Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Synder SH.
Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 1991;351:714-718 12) Nakane M, Schmidt HHW, Pollock JS, Forstermann U, Murad F.Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle FEBS Let. 1993:316:175-180 13) Lyons, CR, Orloff GJ, Cunningham JM. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line J Biol Chem. 1992;267:6370-6374 14) Xie Q, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Ding A,Troso T, Nathan C. Cloning and characterization of inducible nitric oxide synthase from mouse macrophage Science. 1992;256:225-228 15) Lowenstein CJ, Glatt CS, Bredt DS, Synder SH. Cloning and expressed macrophage nitric oxide synthase contrasts with the brain enzyme Proc Natl Acad Sci U.S.A. 1992;89:6711-6715 16) Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK. Di Silvio M, Wang SC, Nakayama DK, Simmons RL, Snyder SH, Billiar TR. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes.
Proc Natl Acad Sci USA. 1993;90:3491-3495 17) Chartrain N, Geller D, Koty P, Sitrin N, Nussler A, Hoffmann E, Billiar T, Hutchinson N, Mudgett J. Molecular cloning,structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J Biol Chem.
1994;269:6765-6772 18) Lamas S, Marsden PA, Gordon KL, Tempst P, Michel T. Endothelial nitric oxide synthase: Molecular cloning and characterization of a distinct constitutive enzyme isoform.Proc Natl Acad Sci. 1992;89:6348-6352 19) Sessa, WC, Harrison JK,Barber CM, Zeng D, Durieux ME, D'Angelo DD, Lynch KR, Peach MJ. Molecular cloning and expression of a c DNA encoding endothelial cell nitric oxide synthase J Bio Chem. 1992;267:15274-15276 20) Nishida K, Harrison DG, Navas JP, Fisher AA, Docery SP, Uematsu M, Nerem RM, Alexander RW, Murphy TJ. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase J Clin Invest. 1992;90:2092-2096 21) Janssens SP, Shimouchi A, Quetermous T, Bloch DB, Bloch KD
Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. - J Biol Chem. 1992;267:14519-14522 22) Marsden PA, Schappert KT, Chen HS, Flowers M, Sundell CL, Wilcox JN, Lamas S, Michel T. Molecular cloning and characterization of human endothelial nitric oxide synthase FEBS Lett. 1992;307:287-293 23) Nadaud S, Bonnardeaux A, Lathrop GM, Soubrier F. Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem Biophys Res Commun. 1994;198:1027-1033 24) Marsden PA, Heng HHQ, Scherer SW, Stewart RJ, Hall AV, Shi XM, Tsui LC, Schappert KT. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem.
1993;268:17478-17488 25) Miyahara K, Kawamoto T, Sase K, Yui Y, Toda K, Yang LX, Hattori R, Aoyama T, Yamamoto Y, Doi Y, Ogoshi S, Hashimoto K, Kawai C, Sasayama S,Shizuta Y. Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene Eur J Biochem. 1994;223:719-726 26) Yasue H, Kugiyama K. Coronary artery spasm: Japanese view.
Coronaryartery disease. 1990;1:668-673 27) Bertrand ME, LaBlanche JM, Tilmant PY, Thieuleux FA, Delforge MR, Carre AG, Asseman PA, Berzin B, Libersa C, Laurent JM. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation. 1982;65:1299-1306 28) Saiki RK, Scharf S, Faloona F,Mullis KB, Horn GT, Erlich HA, Arnheim N. Enzymatic amplification of li -globin genomic sequences and restriction site analysis for diagnosis of sickle ell anemia. Science. 1985;230:1350-29) Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutation and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989;5:874-879 30) Dennis G. Caralis, Ubeydullah Deligonul, Morton J. Kern, Jerome D.
Cohen. Smoking is a risk factor for coronary spas in young women.
10. Circulation. 1992;85:905-909 31) Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation. 1993;87:76-79 32) Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas 0, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149-2155 33) Zeiher AM, Schachinger V, Minners J. Long-term sigarette smoking impairs endothelium-dependent coronary arterial vasodilator function.
Circulation. 1995;92:1094-1100 34) Yasue H, Takizawa A,Nagao M, Nishida S, Horie M, Kubota J, Omote S,Takaoka K, Okumra K. Long-term prognosis for patients with variant angina and influential factors. Circulation.78;1-9:1988 35) Egashira K et.al. Preserved Endothelium-dependent Vasodilation at the Vasospastic Site in Patients with Variant Angina. Endothelial Function and Coronary Vasospasm Vol.89: 1047-1052:1992 33a SEQUENCE LISTING
GENERAL INFORMATION

APPLICANT: Shionogi & Co., Ltd.

TITLE OF INVENTION: Diagnosis of Coronary Artery Spasm-Associated Diseases NUMBER OF SEQUENCES: 72 CORRESPONDENCE ADDRESS: McCarthy Tetrault LLP
Patent & Trademark Agents Suite 4700, P.O. Box 48 66 Wellington Street West Toronto-Dominion Centre Toronto, ON M5K 1E6 COMPUTER-READABLE FORM
COMPUTER: IBM Compatible OPERATING SOFTWARE: Windows 98 SOFTWARE: Word 97 CURRENT APPLICATION DATA
APPLICATION NUMBER: 2,236,809 FILING DATE: November 13, 1996 PRIOR APPLICATION DATA
APPLICATION NUMBER: JP 319504/95 FILING DATE: November 13, 1995 CLASSIFICATION:

PRIOR APPLICATICN DATA
APPLICATION NUMBER: JP 168761/96 FILING DATE: June 28, 1996 CLASSIFICATION:

PATENT AGENT INFORMATION
NAME: McCarthy Tetrault REFERENCE NJMBER: 123579-230174 INFORMATION FOR SEQ ID NO.: 1 SEQUENCE CHARACTERISTICS
LENGTH: 9208 TYPE: DNA
MOLECULE TYPE:Homo Sapies FEATURE
OTHER INFORMATION: nnnnnnnnnn = intervening sequences of ir,trons; residue 133 can be changed from thymine to adenine;
residue 679 can be changed from adenine to guanine; residue 815 can be changed from thymine to cytosine; residue 2374 can be changed from cytosine to thymine; residue 2494 can be changed McCarthy Tetrault LLP TDO-RED #8297632 v. I

33b from guanine to thymine.

SEQUENCE DESCRIPTION: SEQ ID NO.: 1 atctgatgct gcctgtcacc ttgaccctga ggatgccagt cacagctcca ttaactggaa 60 cctaggaaaa tgagtcatcc ttggtcatgc gacatttgca aatggtggct taatatggaa 120 gccagacttg ggttctgttg tctcctcccg catggtagga gatgcctgaa aagtaggggc 180 tggatcccat gccctgcctc actgggaagg cgaggtggtg gggtggggtg gggcctcagg 240 cttggggtca tgggacaaag cccaggctga atgccgccct tccatctccc tcctcctgag 300 acaggggcag cagggcacac tagtgtgcag gagcagctta tgaggcccct tcaccctcca 360 tcctccaaaa ctggcagacc ccaccttctt ggtgtgaccc cagagctctg agcacagccc 420 gttccttccg cctgccggcc ccccacccag gcccacccca accttatcct ccactgcttt 480 tcagaggagt ctggccaaca caaatcctct tgtttgtttg tctgtctgtc tgctgctcct 540 agtctctgcc t.ctcccagtc tctgagcttc cgtttctttc ttaaactttc tctcagtctc 600 tgaggtctcg aaatcacgag gcttcgaccc ctgtggacca gatgcccagc tagtgqcctt 660 tctccagccc ctcagatgac acagaactac aaaccccagc atgcactctg gcctgaagtg 720 cctggagagt gctggtgtac cccacctgca ttctgggaac tgtagtttcc ctagtccccc 780 atgctcccac cagggcatca agctcttccc tggctggctg accctgcctc agccctagtc 840 tctctgctga ctgcggcccc gggaagcgtg cgtcactgaa tgacagggtg ggggtggagg 900 cactggaagg cagcttcctg ctcttttgtg tcccccactt gagtcatggg ggtgtggggg 960 ttccaggaaa ttggggctgg gaggggaagg gataccctaa tgtcagactc aaggacaaaa 1020 agtcactaca tccttgctgg gcctctatcc ccaagaaccc aaaaggactc aagggtgggg 1080 atccaggagt tcttgtatgt atggggggag gtgaaggaga gaacctgcat gaccctagag 1140 gtccctgtgg tcactgagag tgtgggctgc catcccctgc tacagaaacg gtgctcacct 1200 tctgcccaac cctccaggga aaggcacaca ggggtgaggc cgacgttccg tctggtgcca 1260 catcacagaa ggacctttat gaccccctgg tggctctacc ctgccactcc ccaatgcccc 1320 agcccccatg ctgcagcccc agggctctgc tggacacctg ggctcccact tatcagcctc 1380 agtcctcaca gcggaaccca ggcgtccggc cccccaccct tcaggccagc gggcgtggag 1440 ctgaggcttt agagcctccc agccgggctt gttcctgtcc cattqtgtat gggatagggg 1500 cggggcgagg gccagcactg gagagccccc tcccactgcc ccctcctctc ggtcccctcc 1560 ctcttcctaa ggaaaaggcc agggctctgc tggagcaggc agcagagtgg acgcacagta 1620 acatgggcaa cttgaagagc gtggcccagg agcctgggcc accctgcggc ctggggctgg 1680 ggctgggcct tgggctgtgc ggcaagcagg gcccagccac cccggcccct gagcccagcc 1740 gggccccagc atccctactc ccaccagcgc cagaacacag gtaagggcca ggcagctagg 1800 agcaggtggg caacaagggt ggtgtcaagg cctgaagcct ggggctggga aggtctggaa 1860 cttnnnnnnn nnntqgggaa cgccagaagg catgcggcag gtgggctgtg agatcgccag 1920 tgctgtaaca ggggcctccg ggtgacatct gggaaggctg aaaggaaaca aacccttcct 1980 gatgacccta tccctggctc ccaacagccc cccgagctcc ccgctaaccc agcccccaga 2040 ggggcccaag ttccctcgtg tgaagaactg ggaggtgggg agcatcacct atgacaccct 210C
cagcgcccag gcgcagcagg taaggccggc atgccctgtc cccatcgtct ccagggaaag 2160 ggtgggtaag gc.ctggc~tc agatggggcc ggagagggaa gctcaaccct tctttgaatt 2220 ggtcccttgt ttccaaaaag aggagaggac tgggnnnnnn nnnntgcacc cctcctccct 2280 gcccccaact cccatcccac ccctgcaccc tggcctgtcc tgacctttgc actccctcga 2340 cccaggatgg gccctgcacc ccaagacgct gcccgggctc cctggtattt ccacggaaac 2400 tacagggccg gccctccccc ggccccccgg cccctgagca qctgctgagt caggcccggg 2460 acttcatcaa ccagtactac agctccatta agaggtgaca gcttcccgga cgccacagcc 2520 tcccttgtcc cactgaggcc ccagaaaccc cgtgacgacc t.tcccatgnn nnnnnnnnac 2580 acaacttcct gcttgtcccc ttcccacccc tctcctcccc a.ggagcggct cccaggccca 2640 cgaacagcgg cttcaagagg tggaagccga ggtggcagcc acaggcacct accagcttag 2700 ggagagcgag ctggtgttcg gggctaagca ggcctggcgc aacgctcccc gctgcgtggg 2760 ccggatccag tgggggaagc tgcaggtgcg gctggccagc gactqagaga cccgggcgct 2820 accaaaaggg gagcggggtg gcggggcagt tcctaaggct tcccgggggc tgggaggtcc 2880 caaacnnnnn nnnnncctct ggagctgata ctcaagaccc cccgtctctc tcctcaccct 2940 cctctcccgc tqcctcggct ggctcaggtg ttcgatgccc gggactgcag gtctgcacag 3000 McCarthy Tetrault LLP TDO-RF-D 48297632 v. I

I'~ Zf9L6Z8# (73*-OO.L d77)1"v-'1ay dy nDayy 0819 Ee4000eO40 obqooobbbq b6Eoob4obj 4beobqoobb beboz)bbP30 obo5eblob6 OZ19 ooe-4b6ebeo obobeebb-4o bebboeeeoz) oubeo44o4e c)e6ebuoobo obuub6eeoz) 0909 6;ebbe6e6b 6384b;04;0 oebeb46400 boobbEUboo oq64obooae o~ou~bEO~~
0009 ol6beb6bob 6qb6qooooE bobbbeqoeo 4oo5obbeoo oboobeebqb EoboebeEo6 0665 e55eO.Ouuuu uuu1uuT400 04bb444044 6b444b4344 E54uO3b4O4 OeO430b400 0885 4oo4oob-4eb 6b4oaaoobj ouqz)ebjoqo 6qouoobeao obeaoobebq 65Eoojquu6 OZSS qobbEooabb 6qo5b2booq ~o~bbe6bEb 6eoo6bob46 405e60ebu6 6bEDobbb;0 09LS bEob4ob4o6 6obeb6bbob b64oEebbeb b4ob6oEoeo Ebbqbnobqb ~~ob~~~oo6 OOLS objuq4oeou unoe4eub6b oonqabbojo 6bbo44b4bq bqo4q55eoo Z)neob4oz)uD
Ob9S ebopbloeoo 4obebbbeee obqoobbjbo eepobbbqao bqob22obbb 4bbboeez)54 OBSS bbbbebEeOO e34006bbE0 qbbeO4000e Obbb430356 b5e0545e0e 6E0PUee46e OZS9 uo4be65ee6 6ebeebbobb o6bjqo4ooq 6-46bqoEouo e5euqo6qJO qoa eDbeoeE
09bS oj4ob~o-4eb ee}e4#e6b eoobq4o-4oj oo4b4-44o-4b 4qooeeoeb4 b4ouobbbeo 006S ooo4Ej5joo beqouuuuuu uuuube65b6 64118ebEbq b65}qbE6qb EE~p~bE~PE
06ES bboubbo}oo oo4obeueeo e4oooobbaj 4b4ebebb4e b4ouub4abe ub444obebe 08Z5 z)o6DjooDo4 oeoEEEob4e b4z)z)oeeqoe eEEbeeEbqe eeb41qbeqb 4EqoqqoEEe OZZS qj;45eoe:~b b4uuuuuuuu uuo}oebebE 6bebqeebb6 qob4obbbbE eebbEooq~o 09TS eE5eb;56eb E6b4eebebb 000004e6bb 64EE666114 EoeubEooEe ~b6a66~o6~
OOiS b64o6oe5eb oeoEeboqoo o4646546oE b4E4beb4Eb b4e#qbqoo 46beoeuooe 0b05 uoo4qoq6~o :~2oebbEUoo eo6PUeoobb b6booqoD5b beubbbebbe bq6e5eDu5b 0866 Ebbuuuuuuu uuuqobbbeq b5b00034eb }44406bEe6 600440;oeb ebbbbqobEo OZ65 bEJEobue4u bEbaooobbb zobbooebeb oo4obbqeqb 4no4EEoebo 5bEQb4beb3 098b bEebo6b4eb 45boeob56j eojobo4oob ooquqebeeb 45oobo5eob ooaqo4oo44 0086 ooeoeoqooo eoEbbEoooP 054540qoob qooobbebbb bquubqqouo e654qbbbb6 ObLb e6q54#400 OeEEeOO04E qbEO4Oe3OE qoubb64044 b45E36EO00 064000Ebbb 089b 6b43ooeoeo e000004340 2ouoabb6bb 4030Eoeoeo eaooloqobo 333beb6bqo OZ96 Z)uu46bbq6E euob6qbae6 eee}qquoe6 eebes6beo3 eozea6b3oe u6bbeeoobo 09Sb ob4babb6bE e6b~~o~~eb Eoz)bee36lo ;o4oqeo-4eo ooeEz)oo-40o o4OOE44401 OOS6 qaqooqqqoo eEaoqooEbb 650oooo6Eo bEEqoq4Eeq oqo6Eooobb b4oc6o6qoq 066b obb4oeeqoo oeo3ob456e ooe4obuD44 oob63oooqb jouqq4eqoe ez)#542beb 08E6 6e34ao3qqj 006eObb604 OqEou~0=5 ~b~~ebb~~o bbb~~ebeo6 OZ~b looDblobbb 6665eoobbe Ebeobebjee bebb:~ooeob Pebqe~~4-4o 4oobboEOo6 09Z6 ooboeooeoo e6bq6oqeuo eoqbeeeoob eqobeoo44o ou434o4o4o uooo404036 OOZ6 e6q-44bb4o4 bb6464o4b6 ebobbbqe2b eEbbpbb456 qbuuuuuuuu uuob66beob ObTb eobbbbboEq EDb;44b5be eeDbbEabbe oDbbqoEbeo 005bebEDbq b6EQDeqjbe 080b oeo64ob4bo o6b:~boeEo_, Eeebb-4bEob EobbeeoEbe eeb6-4b;ooo 45o-4ooe33e OZOD bbooo2qeb6 4ooebbqeob jo4bqob6:~.6 4ebbeoooob }04}0ooeoe oeoob4ebon 096E eqoDoqbqu4 oae04Eb46D oouoeoooae oDooqujba4 ebabeceeeb 5bZ)e-45qeou 006~ beoa }10ouu uuuuuuuub6 bo-40bb5b1e b6bob}bbeb abbebb;00.4 E0e120ejo6o 068E uEolunoe54 b1b4uoeEbFi EboEobbo4E bEbqneobab qeoeqbbqob bqbeo4qooo 08LE Oubez)b~~~~ q-4be6bqoob bbbb44eeeb b,4ob4ob4eo eEoo;b#)ao b6ouD4ooob OZLE oE46540505 ~~ob6b~u~a bez)64:1;65-4 bebb;DbbPU DOOO20EPOO p0Ece000le 099E bqDbqbb65b aeob}oobbEi Ee6eEoqo4o obeblooole oobbbbbeb6 4ebbbqbbbq 009E oEbZ4ebbbe eeooeabeb4 boeooooeob ebb4oooub4 bbe644oo4b bqo6eboooo OVSE oo5j;Dqqo3j joqoePbeoD ooubebqebe oooob6eob4 54ob4boebo 08bE 440504b5oe EEbbe~~OZ)e b64obboe06 eZ) -4 q eZ) b-4 uq ~bEUEU~~~~
oEmoubbJ04 OZSE ocoooEEbeo ooobeojobb Ebqeobbbeb beblooaqbb bbebbquuuu uuuuuubbbo 09EE qobbeebEbb bqbeooEeeb be6qeebebb q6bEeooooq bj666e6jea oueoobbbeb OOE~ OOEO6b5465 ebooeoqebr b6;boEeoob Eoo~E6bbb6 b054540405 buEbbeobeD
O6ZE bboDe}o66b oboequbob:~ b54a beoube z)Pebb4uqee baoq4oE6Eb be5a ab6loo 08iE abqobobeob 0004464beo eo4eoobboq o6eoob4bob IEDOoo;440 }obEUoebqo OZTE 4obbbbob6e ebbbeobbee oouoq4oq}o o6Eaooobbe 0054eaaeoo oooob46eb4 090E bboqlooeeo 565booeEoa EJJ64eqb2E 04EJEJOEEO 5404Eoe;oo 20445;Eee5 LT-TT-600Z 6089~ZZO VJ

f'" Zf9L6Z8# Q"~'OQ.L d77 JI"-aa.L XNsinJ-,IV
80Z6 oq65eo6-4 ooE67Oboo-; pbq6obbj6P
0816 Ob-4beb6406 bb3a0b00b:1 040004o4be bbOeeEb~~~ 44-4}444:1-44 b44444444:1 0ZY6 444beOe442 b64b:lEO406 eOnoOe-40ob -4 5 eEe-4 0 e10 EEbebbe-4:L b qEbeoobj6j 0906 oEbbbee4ao opqqqebeEb -4:; eq q e-4 11 e 4bPeoqeePq Pee~.bqooeq 0006 ~o:le-4bebbE ~~~4:)-4oobj qoqoo4qabe ~~b~eEbo~b E1,4 o 1 Oq b-4 o Ob68 o6,4oeqoob5 6eooooE-4b6 obeobEoooq ocoobbeebb qo4eeq-4oob ozq6bbqDz)b 0888 b5o~o:)6-4:t5 }oobbE4o4o 4ooo444,4oq ooboeEEeob 2b6eeb6eoo 4o:):j:te:4qe0 0Z88 beo:pebbeE ob~obbebpo z)}bqo4EOeo 4044DOb0bb 266eb44040 000:1004060 09L8 0005eD42b6 ez~oEbaoobo z)q6beoqoe6 aooblubbob eb2bbboojZ 6ez):)-4}ooDj OOL8 q;obb:=ft obe62b4oDo obeoEeoo2o ebeojobboo o:~oaoeft'44 6obb640035 0698 qbEobu6bbb o6q:tb2ortba 6e6beobj,4o oa~q:jobe6e oooeoboE-4e nboob2Eaeb 0858 qbbebbeooo eo6obqo6oe o-4o666~j-4q qEoebEE6oE ooe-4obo2eo beoqebbeoe OZ68 b004q44340 645-40eO34L 540-4a5650-4 5e5004046b eE4zb4Oo-44 6bbbz>b4bDb 0968 E64Oobbbuo 6bbZ)bbbbE6 bz)b-4666z)b:~ obqbab6o-4e oj6z)E5abbo obbeboebbq 0068 ubebbqeo2b obbbebboeb obbqooIEob ob2ob-4booe be0b4 o3 qbo epnoeEnbbj 06~8 Eo 3 e~-4 b-4 eb z)b6nb-4o4b-} -4;b-4eoEoob bbbo6ebo4o o54b-4z)b4bo 63z)E3b4bbe 0838 15b:>6qobb-4o 6eb6oE6b2b ~D04EOebbe z>b4bz)e~Oz)E
0ZZ8 oobooobbb2 ooe~o~~~2a ooboboouuu uuuuuuubz)b Oz 3ebbeb6 b 6Ebe5eb66e 09T8 jEbEEbqooE e4bb4EEobo bbbebqoooe bebq6q66EE aoooeeoebq ouepbbbaoo 00TB jo4qoo5ooe 3qoaqbeboa 56444b46bb bobobEobEo ooboEEbeob 4bbe6oE5ob 0608 ooE4z4o48o oeb44z)EeOJ z)DOb42b;Oz)b 4Ob53-4:4646 6:444D2b4E0 DDq3eoDo5e 086L Ob4Db6bEOb 440b44b566 ODDEEDoOll 00b2bEeb26 60300b4blc eOb 4oBDOD
0Z6L Obbebbbuuu uuuuuuub4o b66b4 bbbbe 6Eoe5b52;,o IEeoPoeo:1b e66beeb~oo 098L b4nabbeEel oeobbbqobPi p54bbeeeob e5e64-4Poeb "4z:)b}ob5n8 ebbeobb'4:)q 00BL TebbbbOOla 3z3;)00644ea b640EO66e0 04bbb4b640 4qez)bqooob 4qobez)ooqe ObLL boooeoob4o bbooajoo4ca oo4obbbEoo b4oo~~~o:~6 qbebb0e540 Debbbbeuuu 089L uuuuuuu4bb 6beb46640e 046462bbe6 4bb4440beO bb4bbbe34b 66EOODb406 0Z9L Eb6b6qbbl} oe6eab6qeb e6q5ee46bb 66ooqeo44o 54ooob464o ooe5e6booo 095L bee04ubeDo bee4Obb450 eu0406:104b e6b4e}z)eob "4z)oooob6b:j 3bbbqebeoo OOSL OOOQ000440 D40400bbDa 2DIDDODbb4 04010000bb 0 0 ebbb4 4 bb 6EOb2OeO3b 066L 610066EObe 55no52Eoee o662bq56be oqoEbbeoeq Lobbqobqbq obEqb4oQoq 08EL noeooqebEb ebbEoJoe:):, DeobEoDoeo 6boqo6eo,b Eo4oeqo24b boocDbEOoq OZEL Ob4D400b40 beOODED400 qDb4uEUooa bqooblobob 646boqbDoo 44beobebb4 09ZL o5466eb64a b}oboeoooc) bloboollbb a b2ebbqb2b bebaPjoboe boooo4Eb5e 003L ooboooo64o oqeob}oeoc, oe2ooqoobb 6bj24obbbe Eb5eqce4qb bebbbEEbee ObtL oq6bbba6bb 5bq6Eo4ob6 E6e2EqDooe euuuuuuuuu ub4eouooo2 eebbeobbq6 080L poooDpbbbb bb:;obeb4eE> b6z)Eba6ebe jobb6beoeo bbebjeeooo oao:Db666b-4 0Z0L 4bbe03be34 00066ebb4a bebbEObEOe e66bEooobE 6eebeo66ja ooEobeo4o6 0969 1066064}04 35eoq3336e oDoeooooja 3e3 4eOE554 004404400e 3404365e33 0069 b3543bOe0b 46ooooob-4--) bbz)o~oz)ebb bob-456b;o6 b~o~~~a}oo obbibbeooo 0689 oqeqoeo6qb 4ooo4obebe o4oo4blooo bbb4obqooq bEobaoe4bb eooobeo4eo 08L9 epeoeoeeee ooEoqbEoEE qoqoqobbeo buuuuuuuuu uooocoEoov Jfieooo64eJ
0ZL9 ooo6Eooeoe obbbEoeeDb eebbb4z)obE obb5bEb4bb 4e0obeO66b eebeb64o5e 0999 Obe6124beob 64b0006e54 oeooo6obbo obauuEbbeb 6q6ab33beb 436188o66e 0099 bbab}qoobb ooob6ooEEo oo6ooo6qo:j 64bbe4eoeo oebbbbboob eooe-45EO5q 0bS9 obb5beb6eo obbe6boo2o e654oobobq 6bqoo-4eoos no6bbebbEo ooonPooooq 0869 z)qoooobqbe Eleooooqoe 6qo4ojonoo eooooobooo qo4qeoeooo 4004004033 0ZV9 Ebb4oooeb4 oz)uEoEE6qc, o46qz)oooez) ooooz)obooe 444obbaEbO ebbe54boe0 OgEg oqbeeobeob eaEOb~aoee ee6bqbeoqo booqeeoe;o bbeooq;bqe bEEbbobbeo 00~9 Eob45o2oo4 e6qojbbEoo ooobooooqo ooobqqqeoq oob4obbEol obeqoonjo6 05Z9 4ooobbaooB bbb4oqo2o5 QeE4oebbbo oon2opoooo obbeblo}oq }bb4o5b.:)OD
PE~

LT-TT-SiO0Z 6089~ZZO VO

1'~ ZF9L6Z8# o32f'O(71 d7711nnqa,L rCy1dnjoyy OZSZ 1000654864 0008p015bbe e6ebb-40520 bebp}bpobb qbooobeb40 1200obobb.00 09bZ 6030ebbe5b q6obooba54 0640bo5bEb b4bqq33b6o o06600Pe~o 06000bqoq6 006Z qbbeqeoeDo e6bbbbDobe ooe4bPob4o bbbbebbeoo bbebbooeoP b54oobDb4b 06~Z b~~o:~Eooea a6bbp5oeoo j5eea 62ob2 eea b;oDeEP ebb}beoqob ou4eeoeqo5 08ZZ bPooqqbqP6 epbbobbPoe o6qbopooj2 bqoqb6eoob qoblqbPobq oobbbe6ozb OZZZ beooobobeb job6oopqbn ebeooba6ee b6lobebboe Epoooobpoq quqeoebebo 09TZ oobooboo6b eeoobqebb,e ba555q54bq 34qooe6eb4 bqoo5oob6e ooqqoo64ob 00TZ beooob6b4o bbpbooqqoo bbebbebbpO obbob46406 pboebo6b6E 006b54o6eo 060Z bqo6qobbob e56b6obbb:j oee6bebbqo 155oeoeo2bb jboob:jbo-4o 6~q-4-jz)6z)b4 086T ~~~~E~oooo pqpofibbooo 1356040666 o}lbqb4bqo 4466polooo aobbb4ooab 0Z6T bbbeobqbeo e6eoeoep;6 1?oo4bEbbpp bbebeeb6ob bo6b-40o-joo 4b-4b5qoeoo 0981 oe6e~qz)b4z) o4o:pobeop P~44z)boz>4p bep4p446eb eeoeob2oep 56z)obb3qoo 0081 00406PoPPD aqo33obboa q5qabe56q2 blooo6406e obqqjcbe6a 3ebb4pabe5 06LT boo3oolebb bbleeb6b14 leoPobEooe elbbqbbqob jbbqoboe6e boPUepboqD
089T ooqbq6bq6o e6q2qbebje b6424bq6qo o}bbbua ooq ebT44qob6P ebboa44oqo 0Z9T pbe5bb54ob pobeopobop }obPb2aDnb bboobbooe6 pbooqobb4P q6qoo4peop 09ST bobbeeb:~bp bobeebobb:F abqbbo2ufib 54eo4o6oqo oboo4oqe5e s546oo6oee OOST oubbqbaebe Pe~~q=e6P e5eebb2oo2 oqeo86ooeo bbbeez)obz)o bqbebbbbee 06bT 660ooooe6e oo6poopqo6 oo4qoobboo oo-46qooqlq 2joe2oq66q ebebbeojeo 08ET oqqq45;ooq opoqoobeo6 b6~qz);e:)oo ooobq6oqeb bjz)obbbqoe beob:~ooobq 0Z~i obb6bbbbeo obbeebpo6p b;ee6e56qo oeo6eebjeo 4qqo4oobbo eoobooboeo 09ZT oeoopbb;6z) qeooeoqbev PoobeqobPa ae~~be~eo6 qo5qboob64 boeeo4eee6 OOZT bqbeo6eo6b ppoe6ppP6b jb4ooo46z)j ooeooPbboo oeqebbqooe bbqPo6ja l6 05TT 4o5646qe6b ebbqooqeoe eoeqobooeo qoooebq6qb qooepb6e6o eobbolebeb 080T 4z)p:)bpb4po Eqbbqobbq6 e:)44oo0Dz)b ez)boooz)4qb ebb4oob6bb 544pPebbqo OZOT bqobqeoepo o4bj6pobbc oolouoboaa bb-4obobloo 6bb4ooo6eo b~-4165:1be6 096 bqobopoooo eobpbbjooc obqbbpbqqo oqbbqofbpbo ooo:)obqz)qj oojjo4o2e6 006 eDz)ooobebq ebeoooobbe ob4obqo5qo ooo6qobjbo eboq4obo}b ba PPE66Poo 068 ooe6bqo6bo eobeoqqPc)E ~~qz)beboz)E o-4ebebbq6z) eeuDbPoooe bbbbb6z)bqb 08L 4o4obboebb eobeobbooe qo6bbo6o24 obob4bbqob PoobpoPebb ja jae6D3q4 0ZL oe5ebbaboo bbloonbqob o6pa6ooojq 6qb2oeoqpu obboqobull oo2eobbbbo 099 e46eeoqaop oopPo54oqe oeqooeo4q6 qPeebbPopo 5qDjb6Qo5j 009 o266booobq ebo44bqb62 o6az)beebb6 bb45eouqeb boobbb4bob 4obooooqo6 06S oeeobcb6qo obbeo6eP-4o 5665olqbqb 64obebobPb P56beqqobe ooeqoue:)56 08~ 2oeoobPobb 456eboobpp b6q6bebe2o q4ob6obeoe eboPooDbbe ooojo6bobe OZt 66ebeel4po o4a beoe4op q62ooeeoqe olloebb6oo ~b62n~6pb~ obqobpobab 09E qoooobbooo ooobboouoo juz)ob5oo6b be0e4osaeb b020044424 5643oD4065 00~ bloobqofboe bpeooooe:)6 jooo656jE6 bEo6eobo5b Eooo5o6Eoq oooeoe6qeq O~Z ooPoqPobpb 6bbqbbe6bb qoeebeebqb qbojoooqqb peooob6bbe 6pooooobeo 08T ujPe4ob~oz) o4o6eboooo oJbea eope6 eJo6JbpoDp lpcbeoooo6 OZT bboobeooob ebqoz)oo6bo Dooeoobeoo obbbpobePo 66z)b4b4jbb bq4oob6b4o 09 6665qo6bbb loobbobloo opoob65qoo bebbpooobb jbobebPPbj loPeobbble Z :'ON QI 03S =NOIZdI2i0S3d SON3[10a5 =N0LLKW2I03NI IdSHZ0 3Nn;LE1S3 suaTdps oiuoH :3dxs 3If103IOW
KNQ = 3d&L
Z19E :HJ,JNSI
SOI.LSI?I3ZOK2i'dH0 30N3(]a3S

Z :'0N CI b3S 2i03 NGIJ.KW2303NI
eEE

LT-TT-500Z 6089~ZZO 1iO

33f ccccccggct gggtgcggga cccccggctg cccccgtgca cgctgcgcca ggctctcacc 2580 ttcttcctgg acatcacctc cccacccagc cctcagctct tgcggctgct cagcaccttg 2640 gcagaagagc ccagggaaca gcaggagctg gaggccctca gccaggatcc ccgacgctac 2700 gaggagtgga agtggttccg ctgccccacg ctgctggagg tgctggagca gttcccgtcg 2760 gtggcgctgc ctgccccact gctcctcacc cagctgcctc tgctccagcc ccggtactac 2820 tcagtcagct cggcacccag cacccaccca ggagagatcc acctcactgt agctgtgctg 2880 gcatacagga ctcaggatgg gctgggcccc ctgcactatg gagtctgctc cacgtggcta 2940 agccagctca agcccggaga ccctgtgccc tgcttcatcc ggggggctcc ctccttccgg 3000 ctgccacccg atcccagctt gccctgcatc ctggtgggtc caggcactgg cattgccccc 3060 ttccggggat tctggcagga gcggctgcat gacattgaga gcaaagqgct gcagcccact 3120 cccatgactt tggtgttcgg ctgccgatgc tcccaacttg accatctcta ccgcgacgag 3180 gtgcagaacg cccagcagcg cggggtgttt ggccgagtcc tcaccgcctt ctcccgggaa 3240 cctgacaacc ccaagaccta cgtgcaggac atcctgagga cggagctggc tgcggaggtg 3300 caccgcgtgc tg=gcctcga gcggggccac atgtttgtct gcggcqatgt taccatggca 3360 accaacgtcc tgcagaccgt gcagcgcatc ctggcgacgg agggcgacat ggagctggac 3420 gaggccggcg acgtcatcgg cgtgctgcgg gatcagcaac gctaccacga agacattttc 3480 gggctcacgc tgcgcaccca ggaggtgaca agccgcatac gcacccagag cttttccttg 3540 caggagcgtc agttgcgggg cgaagtgccc tgggcgttcg accctcccgg ctcagacacc 3600 aacagcccct ga 3612 INFORMATION FOR SEQ ID NO.: 3 SEQUENCE CHARACTERISTICS
LENGTH: 23 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descripti.on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 3 cagcagagtg gacgcacagt aac 23 INFORMATION FOR SEQ ID NO.: 4 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 4 ttgttgccca cctgctccta gctg 24 INFORMATION FOR SEQ ID NO.: 5 McCarthy Tetrault LLP TDO-RED #8297632 v. 1 33q SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descripti_on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 5 aacccttcct gatgacccta tccc 24 INFORMATION FOR SEQ ID NO.: 6 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Syntheti.c Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 6 cttacccacc ctttccctgg agac 24 INFORMATION FOR SEQ ID NO.: 7 SEQUENCE CHARACTERISTICS
LENGTH: 23 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 7 tcctgacctt tqcactccct cga 23 INFORMATION FOR SEQ ID NO.: 8 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers A1cCarthy Tetrault LLP TDO-RED #8297632 v. I

33h SEQUENCE DESCRIPTION: SEQ ID NO.: 8 atgggaaggt cqtcacgggg tttc 24 INFORMATION FOR SEQ ID NO.: 9 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 9 acaacttcct gcttgtcccc ttcc 24 INFORMATION FOR SEQ ID NO.: 10 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descripticn of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 10 accccactcc ccttttggta 20 INFORMATION FOR SEQ ID NO.: 11 SEQUENCE CHARACTERISTICS
LENGTH: 23 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 11 tctggagctg atactcaaga ccc 23 INFORMATION FOR SEQ ID NO.: 12 SEQUENCE CHARACTERISTICS
McCarthy Tetrault LLP TDO-RED #8297632 v. I

33i LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primeis SEQUENCE DESCRIPTION: SEQ ID NO.: 12 cgcatgggga aagagctggt caga 24 INFORMATION FOR SEQ ID NO.: 13 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 13 tctgaccagc tctttcccca tgcg 24 INFORMATION FOR SEQ ID NO.: 14 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript-._on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 14 ccactggttt cctcattctc cacc 24 INFORMATION FOR SEQ ID NO.: 15 SEQUENCE CHARACTERISTICS
LENGTH: 22 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description cf Artificial Sequence:
Synthetic Primers .WcCarthy Tetrautt LLP TDO-RED #8297632 v. I

33j SEQUENCE DESCRIPTION: SEQ ID NO.: 15 aaagcagaag acagtggatg ga 22 INFORMATION FOR SEQ ID NO.: 16 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript;.on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 16 cccagtcaat ccctttggtg ctca 24 INFORMATION FCR SEQ ID NO.: 17 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript;on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 17 gctgatccca caccccaaca 20 INFORMATION FOR SEQ ID NO.: 18 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 18 tgccttggac aggtgcattc 20 INFORMATION FOR SEQ ID NO.: 19 McCarthy TJtrault LLP TDO-RED #8297632 v. I

33k SEQUENCE CHARACTERISTICS
LENGTH: 22 TYPE: DNA
MOLECULE TYPE: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 19 tgatcacctc tgtccctacc ga 22 INFORMATION E'OR SEQ ID NO.: 20 SEQUENCE CHARACTERISTICS
LENGTH: 22 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 20 atgcaaaccc tttqccttcc tg 22 INFORMATION FOR SEQ ID NO.: 21 SEQUENCE CHARACTERISTICS
LENGTH: 23 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 21 aagaatgggc gaggtctgtg ggt 23 INFORMATION FOR SEQ ID NO.: 22 SEQUENCE CHARACTERISTICS
LENGTH: 23 TYPE: DNA
MOLECULE TYPE: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
.WcCarth,y Tetrault LLP TDO-RED i18297632 v. l Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 22 caggggctgc ttagaattag agc 23 INFORMATION FOR SEQ ID NO.: 23 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 23 tccctcccaa cccatcatct ctct 24 INFORMATION FOR SEQ ID NO.: 24 SEQUENCE CHARACTERISTICS
LENGTH: 23 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 24 agtggtaggc ccagaacact gct 23 INF'ORMATION FOR SEQ ID NO.: 25 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 25 caggacaccc tcacaccttc ctct 24 McCarthy Tetrault LLP TDO-lZED #8297632 v. I

33m INFORMATION FOR SEQ ID NO.: 26 SEQUENCE CHARACTERISTICS
LENGTH: 21 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 26 tctttctagc tccctgctcc c 21 INFORMATION FCR SEQ ID NO.: 27 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 27 acagcaccca ggacatctgt cttc 24 INFOR~7F:TION FOR SEQ ID NO.: 28 SEQUENCE CHARACTERISTICS
LENGTH: 23 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 28 agcccctttc ctggaagttc tca 23 INFORMATION FOR SEQ ID NO.: 29 SEQUENCE CHARACTERISTICS
LENGTH: 21 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE

McCarthy Terrault LLP TDO-RED #8297632 v. 1 33n OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 29 tgatgtcaaa cactcccctc g 21 INFORMATION FOR SEQ ID NO.: 30 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 30 aaaacggact tgaggcacag 20 INFORMATION FOR SEQ ID NO.: 31 SEQUENCE CHARACTERISTICS
LENGTH: 21 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 31 gtgacaacct tgtctttgtc c 21 INFORMATION FOR SEQ ID NO.: 32 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 32 tcgtcagtgg agctcccttt 20 McCarthy Tetrault LLP TDO-RED 48297632 v. I

CA 02236809 5"05-11-17 33o INFORMATION FOR SEQ ID NO.: 33 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 33 aaagggagct ccactgacga 20 INFORMATION FOR SEQ ID NO.: 34 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 34 agaatcaggg cagagtgagg 20 INFORMATION FOR SEQ ID NO.: 35 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 35 agcaagacgc agtgaagccg 20 INFORMATION FOR SEQ ID NO.: 36 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE

McCarthy Tetrault LLP TDO-RED #8297632 v. I

33L, OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 36 tggccccaga gtgctttagt 20 INFORMATION FOR SEQ ID NO.: 37 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 37 actaaagcac tctggggcca 20 INFORMATION FOR SEQ ID NO.: 38 SEQUENCE CHARACTERISTICS
LENGTH: 21 TYPE: DNA
N.OLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 38 agggtcaggg tgttcaagac a 21 INFORMATION FOR SEQ ID NO.: 39 SEQUENCE CHARACTERISTICS
LENGTH: 21 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEA~-URE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 39 tgtcctgaac accctgaccc t 21 tilcCarthy Tetrault LLP TDO-RED #8297632 v. 1 33a INFORMATION FOR SEQ ID NO.: 40 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Secuence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 40 qctqgtgtgc cctgttgctt 20 INFORMATION FCR SEQ ID NO.: 41 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript:_on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 41 ctccctgtgc actatcccca 20 INFORMATION FOR SEQ ID NO.: 42 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 42 tctaqcccct qtgcctcatt 20 INFORMATION FOR SEQ ID NO.: 43 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE

McCarthy Tetrault LLP TDO-RED 98297632 v. I

33r OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 43 tccaacccac tgcatcctgc 20 INFORMATION FOR SEQ ID NO.: 44 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 44 tgctcctgct tgttgcctca 20 INFORMATION FCR SEQ ID NO.: 45 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript:-on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 45 tgaggcaaca agcaggagca 20 INFORMATION FOR SEQ ID NO.: 46 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE: Artificial Sequence FEATURE
OTHER INFORMATION: Descript=-cn of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 46 caccaagtct tccatctcac 20 McCarthy Tdtrault LLP TDO-RED #8297632 v. I

33s INFORMATION FOR SEQ ID NO.: 47 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 47 atggagtgtc tctcctgcca 2C
INFORMATION FOR SEQ ID NO.: 48 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 48 ttcaggcagt cctttagtgc 20 INFORMATION FOR SEQ ID NO.: 49 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript:lon of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 49 agaagagcct tcccaacccg 20 INFORMATION FOR SEQ ID NO.: 50 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE

:WcCarthy Tetrault LLP TDO-RED #8297632 v. I

33t OTHER INFbRMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 50 atcttcaggt taccattgcg 20 INFORMATION FOR SEQ ID NO.: 51 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 51 cagacctacg tgcaggacat 20 INFORMATION FOR SEQ ID NO.: 52 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE; DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 52 accttagcag gaaccccgca 20 INFORMATION FOR SEQ ID NO.: 53 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript:ion of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 53 gttctgatcc actgtgctzt 20 McCarthy Tetrault LLP TDO-RED #8297632 v. I

= 33u INFORMATION FOR SEQ ID NO.: 54 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript:ion of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 54 tctcccggaa ctggaaggga 20 INFORMATION FOR SEQ ID NO.: 55 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 55 acaccaacag cccctgagag 20 INFORMATION FOR SEQ ID NO.: 56 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 56 --ggcagtagg ccctggggta 20 INFORMATION FOR SEQ ID NO.: 57 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE

:NcCarthy Tetrautt LLP TDO-R.EU #8297632 v. !

w 33v OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 57 ttaatctgga aggcccctcc 20 INFORMATION FOR SEQ ID NO.: 58 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEA'PURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 58 gagggagact ccgtttcaaa 20 INFORMATION FOR SEQ ID NO.: 59 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript'_on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 59 atgctcccac cagggcatca 20 INFORMATION FOR SEQ ID NO.: 60 SEQUENCE CHARACTERISTICS
LENGTH: 22 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 60 gtccttgagt ctgacattag gg 22 McCarthy Tetrau(t LLP TDO-RED #8297632 v. I

33w INFORMATION FOR SEQ ID NO.: 61 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 61 tcagtctctg aqgtctcgaa 20 INFORMATION FOR SEQ ID NO.: 62 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 62 tgatgccctg gtgggagcat 20 INFORMATION FOR SEQ ID NO.: 63 SEQUENC'E CHARACTERISTICS
LENGTH: 21 TYPE: DNA
MOLECULE TYPE: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 63 ccattaactg gaacctagga a 21 INFORMATION FOR SEQ ID NO.: 64 SEQUENCE CHARACTERISTICS
LENGTH: 21, TYPE: DNA
MOLECULE TYPE: Artificial Sequence FEATURE

.PlcCarthy Tetrault LLP TDO-RED 48297632 v. 1 = CA 02236809 2005-11-17 , 33x OTHER INFORMATION: Descript:.on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 64 agcctgqgct ttgtcccatg a 21 INFORMATION FOR SEQ ID NO.: 65 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 65 tctgaccagc tctttcccca ttcg 24 INFORMATION FOR SEQ ID NO.: 66 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 66 ccactggttt cctcattctc cacc 24 INFORMATION FOR SEQ ID NO.: 67 SEQUENCE CHARACTERISTICS
LENGTH: 18 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 67 ctccagcccc tcagatga 18 McCarthy Tetrault LLP TDO-RED #8297632 v. I

33y INFORMATION FOR SEQ ID NO.: 68 SEQUENCE CHARACTERISTICS
LENGTH: 17 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Descript'-on of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 68 tccagcccct cagatgg 17 INFORMATION FOR SEQ ID NO.: 69 SEQUENCE CHARACTERISTICS
LENGTH: 22 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 69 gtccttgagt ctgacattag gg 22 INFORMATION FOR SEQ ID NO.: 70 SEQUENCE CHARACTERISTICS
LENGT}I : 21 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 70 aatgagtcat ccttggtcat g 21 INFORMATION FOR SEQ ID NO.: 71 SEQUENCE CHARACTERISTICS
LENGTH: 18 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE

AfcCarthy Tetrault LLP TDO-RED #8297632 v. 1 = CA 02236809 2005-11-17 33z OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 71 gggtttgtag ttctgtgt 18 INFORMATION FOR SEQ ID NO.: 72 SEQUENCE CHARACTERISTICS
LENGTH: 18 TYPE: DNA
MOLECULE TYPE:Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic Primers SEQUENCE DESCRIPTION: SEQ ID NO.: 72 gggtttqtag ttctgtgc 18 McCarthy Tgtrault LLP TDO-RED #8297632 v. I

Claims (12)

1. A process for screening for a gene involving a coronary artery spasm-associated disease, comprising:
obtaining a DNA sample from a subject to be tested for a coronary artery spasm-associated disease; and detecting the presence of one or more nucleotide changes in a gene encoding human endothelial nitric oxide synthase (eNOS), which changes are selected from the group consisting of the changes in the eNOS cDNA sequence from guanine (G) to thymine (T) at position 894 and from cytosine (C) to thymine (T) at position 774 of SEQ
ID NO:2, and the changes in the 5' flanking region of the human eNOS gene from thymine (T) to cytosine (C) at position 815, from adenine (A) to guanine (G) at position 679, and from thymine (T) to adenine (A) at position 133 of SEQ ID NO: 1, and changes at the corresponding positions in the complementary strands thereof.

2. The process of claim 1, in which the detecting step comprises detecting the presence of two or more nucleotide changes selected from any one of the nucleotide changes in the eNOS gene and any one of the nucleotide changes in the 5'-flanking region thereof.

3. The process of any one of claims 1 to 2, in which the coronary artery spasm-associated disease is angina.

4. The process of claim 3, in which the coronary artery spasm-associated disease is coronary spastic angina.

5. The process of claim 1, in which the detecting step is performed by amplifying the relevant region of exon 7 in the cDNA coding eNOS by means of PCR, digesting the amplified fragments with the restriction enzyme(s) BanII and/or MboI, and electrophoresing the fragments digested with the enzyme.

6. A diagnostic coronary artery spasm-associated disease kit, comprising:
a pair of amplification oligonucleotides for amplifying the relevant portion of exon 7 in SEQ ID NO:2 in the cDNA coding eNOS by PCR; and the restriction enzyme(s) BanII and/or MboI.

7. The process of claim 1, in which the detecting step is performed by amplifying the relevant region of exon 6 in the cDNA coding eNOS by means of PCR, digesting the amplified fragments with the restriction enzyme FokI, and electrophoresing the fragments digested with the enzyme.

8. A diagnostic coronary artery spasm-associated disease kit, comprising:
a pair of amplification oligonucleotides for amplifying the relevant portion of exon 6 in SEQ ID NO:2 in the cDNA coding eNOS by PCR; and the restriction enzyme FokI.

9. The process of claim 1, in which the detecting step is performed by amplifying a portion encompassing the 815 position in SEQ ID NO:1 in the 5'-flanking region of the eNOS gene by means of PCR, digesting the amplified fragments with the restriction enzyme MspI, and electrophoresing the fragments digested with the enzyme.

10. A diagnostic coronary artery spasm-associated disease kit, comprising:
a pair of amplification oligonucleotides for amplifying a portion encompassing the 815 position in SEQ ID NO:1 in the 5'-flanking region of a gene encoding eNOS by PCR; and the restriction enzyme MspI.

11. The process of claim 1, in which the detecting step is performed by amplifying a portion encompassing the 133 position in SEQ ID NO:1 in the 5'-flanking region of a gene encoding eNOS by means of PCR, digesting the amplified fragments with the restriction enzyme MboI, and electrophoresing the fragments digested with the enzyme.

12. A diagnostic coronary artery spasm-associated disease kit, comprising:
a pair of amplification oligonucleotides for amplifying a portion encompassing the 133 position in SEQ ID NO:1 in the 5'-flanking region of a gene encoding eNOS by PCR; and the restriction enzyme MboI.